The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 13, 2026

Filed:

May. 02, 2025
Applicants:

Baxter International Inc., Deerfield, IL (US);

Baxter Healthcare SA, Glattpark, CH;

Inventors:

Jane Werling, Arlington Heights, IL (US);

Melissa R. Wilson, Ingleside, IL (US);

Amanda Bayer, Waunakee, WI (US);

Assignees:

BAXTER INTERNATIONAL INC., Deerfield, IL (US);

BAXTER HEALTHCARE SA, Glattpark, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7052 (2006.01); A61K 47/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7052 (2013.01); A61K 47/02 (2013.01);
Abstract

An aseptically prepared pharmaceutically acceptable azithromycin premix formulation has a pH value of 5.5 to 7.5, preferably 6.0 to 7.0, more preferably 6.3 to 7.0, even more preferably 6.3 to 6.7, for example about 6.5. Preferred embodiments of the aseptically prepared pharmaceutically acceptable azithromycin premix formulation contain azithromycin, a buffering agent, water and optionally a tonicity adjusting agent and are stable for one month, three months, six months, nine months, twelve months, fifteen months, eighteen months or even twenty-four months, during storage at refrigerated temperatures, such as about 5° C., even without any additional components beyond the azithromycin, the buffering agent, and the optional tonicity adjusting agent in the premix formulation. The pharmaceutically acceptable azithromycin premix formulation may be aseptically filled into a container, preferably a glass or flexible container, to form a sterile pharmaceutical azithromycin premix product which does not undergo terminal sterilization. The azithromycin premix product can be a single use premix which is a sterile, stable and ready-to-use aqueous solution for parenteral administration, for example intravenous (IV) administration such as IV infusion, and requires no dilution prior to parenteral administration.


Find Patent Forward Citations

Loading…